Evidence map›Paper›PMID 35937950›Full record

ArticleInternational journal of cardiology. Heart & vasculature2022

Elevated Lipoprotein(a) prevalence and association with family history of premature cardiovascular disease in general population with moderate cardiovascular risk and increased LDL cholesterol.

Pablo E Gulayin, Alfredo Lozada, Laura Schreier, Laura Gutierrez, Graciela López, Rosana Poggio, Nora Mores, Jacqueline Ponzo, Matías Calandrelli, Fernando Lanas and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of cardiology. Heart & vasculature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Date (Plants (Basel, Switzerland) · 2024
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Pablo E GulayinInstitute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina.
Alfredo LozadaCentro de Lípidos, Universidad Austral, Argentina.
Laura SchreierUniversidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Hospital de Clínicas, Lab de Lípidos y Aterosclerosis, INFIBIOC-UBA, Argentina.
Laura GutierrezInstitute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina.
Graciela LópezUniversidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Hospital de Clínicas, Lab de Lípidos y Aterosclerosis, INFIBIOC-UBA, Argentina.
Rosana PoggioInstitute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina.
Nora MoresMunicipalidad de Marcos Paz, Argentina.
Jacqueline PonzoFacultad de Medicina, Universidad de la República, Montevideo, Uruguay.
Matías CalandrelliSanatorio San Carlos, Bariloche, Argentina.
Fernando LanasUniversidad de La Frontera, Temuco, Chile.
Vilma IrazolaInstitute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina.
Instituto de Efectividad Clínica y Sanitaria · ARBariloche Atomic Centre · ARUniversidad de La Frontera · CLUniversidad de la República · UYUniversidad Nacional de La Plata · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Elevated Lipoprotein(a) [Lp(a)] is independently associated with increased cardiovascular disease (CVD) risk. There are discrepancies regarding its epidemiology due to great variability in different populations. This study aimed to evaluate the prevalence of elevated Lp(a) in people with moderate CVD risk and increased LDL-c and to determine the association between family history of premature CVD and elevated Lp(a). Methods: Random subjects from the CESCAS population-based study of people with moderate CVD risk (Framingham score 10-20 %) and LDL-c ≥ 130 mg/dL, were selected to evaluate Lp(a) by immunoturbidimetry independent of the Isoforms variability. The association between family history of premature CVD and elevated Lp(a) was evaluated using multivariate logistic regression models. Elevated Lp(a) was defined as Lp(a) ​​≥ 125 nmol/L. Results: Lp(a) was evaluated in 484 samples; men = 39.5 %, median age = 57 years (Q1-Q3: 50-63), mean CVD risk = 14.4 % (SE: 0.2), family history of premature CVD = 11.2 %, Lp(a) median of 21 nmol/L (Q1-Q3: 9-42 nmol/L), high Lp(a) = 6.1 % (95 % CI = 3.8-9.6). Association between family history of premature CVD and elevated Lp(a) in total population: OR 1.31 (95 % CI = 0.4, 4.2) p = 0.642; in subgroup of people with LDL-c ≥ 160 mg%, OR 4.24 (95 % CI = 1.2, 15.1) p = 0.026. Conclusions: In general population with moderate CVD risk and elevated LDL-c from the Southern Cone of Latin America, less than one over ten people had elevated Lp(a). Family history of premature CVD was significantly associated with the presence of elevated Lp(a) in people with LDL-c ≥ 160 mg/dL.

Indexed as

Cardiovascular disease riskCVD family historyLDL cholesterolLipoprotein(a)

Identifiers

PMID35937950
PMCPMC9352902
OpenAlexW4288987476

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.